Classification of Pulmonary Hypertension

Heart Failure Clinics

Volumn 8, Issue 3, 2012, Pages 301-317

  McGlothlin, Dana ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Hemodynamics; Pulmonary arterial hypertension; Pulmonary hypertension; WHO classification

Indexed keywords

ACTININ RECEPTOR LIKE KINASE TYPE 1; AMINOREX; ANTINEOPLASTIC AGENT; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; COCAINE; DEXFENFLURAMINE; DIURETIC AGENT; ENDOGLIN; FENFLURAMINE; HYPERICUM PERFORATUM EXTRACT; PHENYLPROPANOLAMINE; RAPESEED OIL; SEROTONIN UPTAKE INHIBITOR; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ALTITUDE DISEASE; ALVEOLAR HYPOVENTILATION DISORDER; ANEMIA; CHRONIC HEMOLYTIC ANEMIA; CHRONIC KIDNEY FAILURE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; CONGENITAL HEART DISEASE; CONNECTIVE TISSUE DISEASE; DEVELOPMENTAL DISORDER; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG EXPOSURE; DRUG INDUCED PULMONARY HYPERTENSION; FIBROSING MEDIASTINITIS; GAUCHER DISEASE; GENE MUTATION; GLYCOGEN STORAGE DISEASE; HEART ATRIUM SEPTUM DEFECT; HEART CATHETERIZATION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE FILLING PRESSURE; HERITABLE PULMONARY HYPERTENSION; HISTIOCYTOSIS X; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERICUM PERFORATUM; HYPOXIA; IDIOPATHIC PULMONARY HYPERTENSION; INTERSTITIAL LUNG DISEASE; LUNG ARTERY PRESSURE; LUNG HEMODYNAMICS; LYMPHANGIOLEIOMYOMATOSIS; MYELOPROLIFERATIVE DISORDER; NEUROFIBROMATOSIS; PATENT DUCTUS ARTERIOSUS; PERSISTENT PULMONARY HYPERTENSION OF THE NEWBORN; PH MEASUREMENT; PORTAL HYPERTENSION; PULMONARY CAPILLARY HEMANGIOMATOSIS; PULMONARY HYPERTENSION; PULMONARY VENO-OCCLUSIVE DISEASE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SARCOIDOSIS; SCHISTOSOMIASIS; SEX RATIO; SLEEP DISORDERED BREATHING; SPLENECTOMY; SYSTEMIC PULMONARY SHUNT; THYROID DISEASE; TOXIC INDUCED PULMONARY HYPERTENSION; TUMORAL OBSTRUCTION; VASCULITIS;

BLOOD PRESSURE; CHRONIC DISEASE; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; PULMONARY ARTERY; PULMONARY VEINS; RISK FACTORS; WORLD HEALTH ORGANIZATION;

EID: 84863101442     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2012.04.013     Document Type: Review

References (165)

1. Kovacs G., Berghold A., Scheidl S., et al. Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J 2009, 34(4):888-894.
2. Naeije R., Melot C., Niset G., et al. Mechanisms of improved arterial oxygenation after peripheral chemoreceptor stimulation during hypoxic exercise. J Appl Phys 1993, 74(4):1666-1671.
3. Chatterjee K., De Marco T., Alpert J.S. Pulmonary hypertension: hemodynamic diagnosis and management. Arch Intern Med 2002, 162(17):1925-1933.
4. Oudiz R.J. Pulmonary hypertension associated with left-sided heart disease. Clin Chest Med 2007, 28(1):233-241. x.
5. Capomolla S., Febo O., Guazzotti G., et al. Invasive and non-invasive determinants of pulmonary hypertension in patients with chronic heart failure. J Heart Lung Transplant 2000, 19(5):426-438.
6. Drazner M.H., Hamilton M.A., Fonarow G., et al. Relationship between right and left-sided filling pressures in 1000 patients with advanced heart failure. J Heart Lung Transplant 1999, 18(11):1126-1132.
7. Drazner M.H., Prasad A., Ayers C., et al. The relationship of right- and left-sided filling pressures in patients with heart failure and a preserved ejection fraction. Circ Heart Fail 2010, 3(2):202-206.
8. Enriquez-Sarano M., Rossi A., Seward J.B., et al. Determinants of pulmonary hypertension in left ventricular dysfunction. J Am Coll Cardiol 1997, 29(1):153-159.
9. Costard-Jackle A., Fowler M.B. Influence of preoperative pulmonary artery pressure on mortality after heart transplantation: testing of potential reversibility of pulmonary hypertension with nitroprusside is useful in defining a high risk group. J Am Coll Cardiol 1992, 19(1):48-54.
10. Abramson S.V., Burke J.F., Kelly J.J., et al. Pulmonary hypertension predicts mortality and morbidity in patients with dilated cardiomyopathy. Ann Intern Med 1992, 116(11):888-895.
11. Zener J.C., Hancock E.W., Shumway N.E., et al. Regression of extreme pulmonary hypertension after mitral valve surgery. Am J Cardiol 1972, 30(8):820-826.
12. Braunwald E., Braunwald N.S., Ross J., et al. Effects of mitral-valve replacement on the pulmonary vascular dynamics of patients with pulmonary hypertension. N Engl J Med 1965, 273:509-514.
13. Simonneau G., Robbins I.M., Beghetti M., et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009, 54(Suppl 1):S43-S54.
14. Hatano S., Strasser T. Primary pulmonary hypertension. Report on a WHO meeting 1975, World Health Organization, Geneva (Switzerland).
15. Fishman A.P. Clinical classification of pulmonary hypertension. Clin Chest Med 2001, 22(3):385-391. vii.
16. Simonneau G., Galiè N., Rubin L.J., et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004, 43(12 Suppl S):5S-12S.
17. Humbert M., Sitbon O., Chaouat A., et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006, 173(9):1023-1030.
18. Badesch D.B., Raskob G.E., Elliott C.G., et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest 2010, 137(2):376-387.
19. Rich S., Dantzker D.R., Ayres S.M., et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987, 107(2):216-223.
20. Chaouat A., Coulet F., Favre C., et al. Endoglin germline mutation in a patient with hereditary haemorrhagic telangiectasia and dexfenfluramine associated pulmonary arterial hypertension. Thorax 2004, 59(5):446-448.
21. Trembath R.C. Mutations in the TGF-beta type 1 receptor, ALK1, in combined primary pulmonary hypertension and hereditary haemorrhagic telangiectasia, implies pathway specificity. J Heart Lung Transplant 2001, 20(2):175.
22. Sztrymf B., Coulet F., Girerd B., et al. Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation. Am J Respir Crit Care Med 2008, 177(12):1377-1383.
23. Rosenzweig E.B., Morse J.H., Knowles J.A. Clinical implications of determining BMPR2 mutation status in a large cohort of children and adults with pulmonary arterial hypertension. J Heart Lung Transplant 2008, 27:668-674.
24. Girerd B., Montani D., Coulet F., et al. Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation. Am J Respir Crit Care Med 2010, 181(8):851-861.
25. Machado R.D., Aldred M.A., James V., et al. Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension. Hum Mutat 2006, 27(2):121-132.
26. Thomson J.R., Machado R.D., Pauciulo M.W., et al. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family. J Med Genet 2000, 37(10):741-745.
27. Girerd B., Montani D., Eyries M., et al. Absence of influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension. Respir Res 2010, 11:73.
28. Abenhaim L., Moride Y., Brenot F., et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med 1996, 335(9):609-616.
29. Walker A.M., Langleben D., Korelitz J.J., et al. Temporal trends and drug exposures in pulmonary hypertension: an American experience. Am Heart J 2006, 152(3):521-526.
30. Simonneau G., Fartoukh M., Sitbon O., et al. Primary pulmonary hypertension associated with the use of fenfluramine derivatives. Chest 1998, 114(Suppl 3):195S-199S.
31. Chambers C.D., Hernandez-Diaz S., Van Marter L.J., et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006, 354(6):579-587.
32. Schaiberger P.H., Kennedy T.C., Miller F.C., et al. Pulmonary hypertension associated with long-term inhalation of " crank" methamphetamine. Chest 1993, 104(2):614-616.
33. Wu L.T., Schlenger W.E., Galvin D.M. Concurrent use of methamphetamine, MDMA, LSD, ketamine, GHB, and flunitrazepam among American youths. Drug Alcohol Depend 2006, 84(1):102-113.
34. Chin K.M., Channick R.N., Rubin L.J. Is methamphetamine use associated with idiopathic pulmonary arterial hypertension?. Chest 2006, 130(6):1657-1663.
35. Wigley F.M., Lima J.A., Mayes M., et al. The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study). Arthritis Rheum 2005, 52(7):2125-2132.
36. Hachulla E., Gressin V., Guillevin L., et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005, 52(12):3792-3800.
37. Mukerjee D., St George D., Coleiro B., et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003, 62(11):1088-1093.
38. Avouac J., Airò P., Meune C., et al. Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies. J Rheumatol 2010, 37(11):2290-2298.
39. Condliffe R., Kiely D.G., Peacock A.J., et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009, 179(2):151-157.
40. Asherson R.A. Pulmonary hypertension in systemic lupus erythematosus. J Rheumatol 1990, 17(3):414-415.
41. Tanaka E., Harigai M., Tanaka M., et al. Pulmonary hypertension in systemic lupus erythematosus: evaluation of clinical characteristics and response to immunosuppressive treatment. J Rheumatol 2002, 29(2):282-287.
42. Jais X., Launay D., Yaici A., et al. Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. Arthritis Rheum 2008, 58(2):521-531.
43. Launay D., Hachulla E., Hatron P.Y., et al. Pulmonary arterial hypertension: a rare complication of primary Sjogren syndrome: report of 9 new cases and review of the literature. Medicine (Baltimore) 2007, 86(5):299-315.
44. Dawson J.K., Goodson N.G., Graham D.R., et al. Raised pulmonary artery pressures measured with Doppler echocardiography in rheumatoid arthritis patients. Rheumatology (Oxford) 2000, 39(12):1320-1325.
45. Bunch T.W., Tancredi R.G., Lie J.T. Pulmonary hypertension in polymyositis. Chest 1981, 79(1):105-107.
46. Le Pavec J., Humbert M., Mouthon L., et al. Systemic sclerosis-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2010, 181(12):1285-1293.
47. Launay D., Mouthon L., Hachulla E., et al. Prevalence and characteristics of moderate to severe pulmonary hypertension in systemic sclerosis with and without interstitial lung disease. J Rheumatol 2007, 34(5):1005-1011.
48. Kim K.K., Factor S.M. Membranoproliferative glomerulonephritis and plexogenic pulmonary arteriopathy in a homosexual man with acquired immunodeficiency syndrome. Hum Pathol 1987, 18(12):1293-1296.
49. Degano B., Guillaume M., Savale L., et al. HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era. AIDS 2010, 24(1):67-75.
50. Almodovar S., Cicalini S., Petrosillo N., et al. Pulmonary hypertension associated with HIV infection: pulmonary vascular disease: the global perspective. Chest 2010, 137(Suppl 6):6S-12S.
51. Mehta N.J., Khan I.A., Mehta R.N., et al. HIV-Related pulmonary hypertension: analytic review of 131 cases. Chest 2000, 118(4):1133-1141.
52. Opravil M., Pechère M., Speich R., et al. HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study. Am J Respir Crit Care Med 1997, 155(3):990-995.
53. Sitbon O., Lascoux-Combe C., Delfraissy J.F., et al. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med 2008, 177(1):108-113.
54. Cicalini S., Almodovar S., Grilli E., et al. Pulmonary hypertension and human immunodeficiency virus infection: epidemiology, pathogenesis, and clinical approach. Clin Microbiol Infect 2011, 17(1):25-33.
55. Petitpretz P., Brenot F., Azarian R., et al. Pulmonary hypertension in patients with human immunodeficiency virus infection. Comparison with primary pulmonary hypertension. Circulation 1994, 89(6):2722-2727.
56. Humbert M., Monti G., Fartoukh M., et al. Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur Respir J 1998, 11(3):554-559.
57. Kanmogne G.D., Primeaux C., Grammas P. HIV-1 gp120 proteins alter tight junction protein expression and brain endothelial cell permeability: implications for the pathogenesis of HIV-associated dementia. J Neuropathol Exp Neurol 2005, 64(6):498-505.
58. Kim J., Ruff M., Karwatowska-Prokopczuk E., et al. HIV envelope protein gp120 induces neuropeptide Y receptor-mediated proliferation of vascular smooth muscle cells: relevance to AIDS cardiovascular pathogenesis. Regul Pept 1998, 75-76:201-205.
59. Rusnati M., Presta M. HIV-1 Tat protein and endothelium: from protein/cell interaction to AIDS-associated pathologies. Angiogenesis 2002, 5(3):141-151.
60. Le Pavec J., Souza R., Herve P., et al. Portopulmonary hypertension: survival and prognostic factors. Am J Respir Crit Care Med 2008, 178(6):637-643.
61. Krowka M. Portopulmonary hypertension. Semin Respir Crit Care Med 2012, 33(1):17-25.
62. Hadengue A., Benhayoun M.K., Lebrec D., et al. Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics. Gastroenterology 1991, 100(2):520-528.
63. Krowka M.J., Swanson K.L., Frantz R.P., et al. Portopulmonary hypertension: results from a 10-year screening algorithm. Hepatology 2006, 44(6):1502-1510.
64. Krowka M.J., Miller D.P., Barst R.J., et al. Portopulmonary hypertension: a report from the US-based REVEAL registry. Chest 2012, 141(4):906-915.
65. Kidd L., Driscoll D.J., Gersony W.M., et al. Second natural history study of congenital heart defects. Results of treatment of patients with ventricular septal defects. Circulation 1993, 87(Suppl 2):I38-I51.
66. Steele P.M., Fuster V., Cohen M., et al. Isolated atrial septal defect with pulmonary vascular obstructive disease-long-term follow-up and prediction of outcome after surgical correction. Circulation 1987, 76(5):1037-1042.
67. Diller G.P., Gatzoulis M.A. Pulmonary vascular disease in adults with congenital heart disease. Circulation 2007, 115(8):1039-1050.
68. Galie N., Manes A., Palazzini M., et al. Management of pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts and Eisenmenger's syndrome. Drugs 2008, 68(8):1049-1066.
69. Duffels M.G., Engelfriet P.M., Berger R.M., et al. Pulmonary arterial hypertension in congenital heart disease: an epidemiologic perspective from a Dutch registry. International journal of cardiology 2007, 120(2):198-204.
70. dos Santos Fernandes C.J., Jardim C.V., Hovnanian A., et al. Survival in schistosomiasis-associated pulmonary arterial hypertension. J Am Coll Cardiol 2010, 56(9):715-720.
71. Lapa M., Dias B., Jardim C., et al. Cardiopulmonary manifestations of hepatosplenic schistosomiasis. Circulation 2009, 119(11):1518-1523.
72. Steinmann P., Keiser J., Bos R., et al. Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect Dis 2006, 6(7):411-425.
73. Barnett C.F., Hsue P.Y., Machado R.F. Pulmonary hypertension: an increasingly recognized complication of hereditary hemolytic anemias and HIV infection. JAMA 2008, 299(3):324-331.
74. Machado R.F., Gladwin M.T. Pulmonary hypertension in hemolytic disorders: pulmonary vascular disease: the global perspective. Chest 2010, 137(SUPPL. 6):30S-38S.
75. Morris C.R., Kato G.J., Poljakovic M., et al. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA 2005, 294(1):81-90.
76. Ergul S., Brunson C.Y., Hutchinson J., et al. Vasoactive factors in sickle cell disease: in vitro evidence for endothelin-1-mediated vasoconstriction. Am J Hematol 2004, 76(3):245-251.
77. Gladwin M.T., Sachdev V., Jison M.L., et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004, 350(9):886-895.
78. Parent F., Bachir D., Inamo J., et al. A hemodynamic study of pulmonary hypertension in sickle cell disease. N Engl J Med 2011, 365(1):44-53.
79. Ostrea E.M., Villanueva-Uy E.T., Natarajan G., et al. Persistent pulmonary hypertension of the newborn: pathogenesis, etiology, and management. Paediatr Drugs 2006, 8(3):179-188.
80. Stayer S.A., Liu Y. Pulmonary hypertension of the newborn. Best Pract Res Clin Anaesthesiol 2010, 24(3):375-386.
81. Montani D., O'Callaghan D.S., Savale L., et al. Pulmonary veno-occlusive disease: recent progress and current challenges. Respir Med 2010, 104(Suppl 1):S23-S32.
82. Montani D., Price L.C., Dorfmuller P., et al. Pulmonary veno-occlusive disease. Eur Respir J 2009, 33(1):189-200.
83. Lantuejoul S., Sheppard M.N., Corrin B., et al. Pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis: a clinicopathologic study of 35 cases. Am J Surg Pathol 2006, 30(7):850-857.
84. Johnson S.R., Patsios D., Hwang D.M., et al. Pulmonary veno-occlusive disease and scleroderma associated pulmonary hypertension. J Rheumatol 2006, 33(11):2347-2350.
85. Guazzi M., Arena R. Pulmonary hypertension with left-sided heart disease. Nature reviews. Cardiology 2010, 7(11):648-659.
86. Guglin M., Khan H. Pulmonary hypertension in heart failure. J Card Fail 2010, 16(6):461-474.
87. Hoeper M.M., Barberà J.A., Channick R.N., et al. Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. J Am Coll Cardiol 2009, 54(Suppl 1):S85-S96.
88. Lam C.S., Roger V.L., Rodeheffer R.J., et al. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol 2009, 53(13):1119-1126.
89. Bursi F., McNallan S.M., Redfield M.M., et al. Pulmonary pressures and death in heart failure: a community study. J Am Coll Cardiol 2012, 59(3):222-231.
90. Kalogeropoulos A.P., Vega J.D., Smith A.L., et al. Pulmonary hypertension and right ventricular function in advanced heart failure. Congest Heart Fail 2011, 17(4):189-198.
91. Ben-Dor I., Goldstein S.A., Pichard A.D., et al. Clinical profile, prognostic implication, and response to treatment of pulmonary hypertension in patients with severe aortic stenosis. Am J Cardiol 2011, 107(7):1046-1051.
92. Cappola T.P., Felker G.M., Kao W.H., et al. Pulmonary hypertension and risk of death in cardiomyopathy: patients with myocarditis are at higher risk. Circulation 2002, 105(14):1663-1668.
93. Kjaergaard J., Akkan D., Iversen K.K., et al. Prognostic importance of pulmonary hypertension in patients with heart failure. Am J Cardiol 2007, 99(8):1146-1150.
94. Ghio S., Gavazzi A., Campana C., et al. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol 2001, 37(1):183-188.
95. Grigioni F., Potena L., Galiè N., et al. Prognostic implications of serial assessments of pulmonary hypertension in severe chronic heart failure. J Heart Lung Transplant 2006, 25(10):1241-1246.
96. Khush K.K., Tasissa G., Butler J., et al. Effect of pulmonary hypertension on clinical outcomes in advanced heart failure: analysis of the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) database. Am Heart J 2009, 157(6):1026-1034.
97. Dadfarmay S., Berkowitz R., Kim B., et al. Differentiating pulmonary arterial and pulmonary venous hypertension and the implications for therapy. Congest Heart Fail 2010, 16(6):287-291.
98. Moraes D.L., Colucci W.S., Givertz M.M. Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management. Circulation 2000, 102(14):1718-1723.
99. Behr J., Ryu J.H. Pulmonary hypertension in interstitial lung disease. Eur Respir J 2008, 31(6):1357-1367.
100. Chaouat A., Naeije R., Weitzenblum E. Pulmonary hypertension in COPD. Eur Respir J 2008, 32(5):1371-1385.
101. Lettieri C.J., Nathan S.D., Barnett S.D., et al. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 2006, 129(3):746-752.
102. Scharf S.M., Iqbal M., Keller C., et al. Hemodynamic characterization of patients with severe emphysema. Am J Respir Crit Care Med 2002, 166(3):314-322.
103. Shorr A.F., Helman D.L., Davies D.B., et al. Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics. Eur Respir J 2005, 25(5):783-788.
104. Shorr A.F., Wainright J.L., Cors C.S., et al. Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant. Eur Respir J 2007, 30(4):715-721.
105. Thabut G., Dauriat G., Stern J.B., et al. Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest 2005, 127(5):1531-1536.
106. Weitzenblum E., Moyses B., Methlin G. Relationship between pulmonary artery mean pressure and the vertical gradient of perfusion in chronic respiratory diseases. Respiration 1984, 46(4):337-341.
107. Cottin V., LePavec J., Prévot G., et al. Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. Eur Respir J 2010, 35(1):105-111.
108. Cottin V., Nunes H., Brillet P.Y., et al. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J 2005, 26(4):586-593.
109. Hamada K., Nagai S., Tanaka S., et al. Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis. Chest 2007, 131(3):650-656.
110. Weitzenblum E., Hirth C., Ducolone A., et al. Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease. Thorax 1981, 36(10):752-758.
111. Patel N.M., Lederer D.J., Borczuk A.C., et al. Pulmonary hypertension in idiopathic pulmonary fibrosis. Chest 2007, 132(3):998-1006.
112. Todd N.W., Lavania S., Park M.H., et al. Variable prevalence of pulmonary hypertension in patients with advanced interstitial pneumonia. J Heart Lung Transplant 2010, 29(2):188-194.
113. Stolz D., Rasch H., Linka A., et al. A randomised, controlled trial of bosentan in severe COPD. Eur Respir J 2008, 32(3):619-628.
114. Group N.O.T.T. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med 1980, 93(3):391-398.
115. Party B.M.R.C. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet 1981, 1(8222):681-686.
116. Steen V.D., Graham G., Conte C., et al. Isolated diffusing capacity reduction in systemic sclerosis. Arthritis Rheum 1992, 35(7):765-770.
117. Minai O.A., Ricaurte B., Kaw R., et al. Frequency and impact of pulmonary hypertension in patients with obstructive sleep apnea syndrome. Am J Cardiol 2009, 104(9):1300-1306.
118. Kasai T., Bradley T.D. Obstructive sleep apnea and heart failure: pathophysiologic and therapeutic implications. J Am Coll Cardiol 2011, 57(2):119-127.
119. Young T., Palta M., Dempsey J., et al. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 1993, 328(17):1230-1235.
120. Hackett P.H., Roach R.C. High-altitude illness. N Engl J Med 2001, 345(2):107-114.
121. Maignan M., Rivera-Ch M., Privat C., et al. Pulmonary pressure and cardiac function in chronic mountain sickness patients. Chest 2009, 135(2):499-504.
122. Bailey D.M., Dehnert C., Luks A.M., et al. High-altitude pulmonary hypertension is associated with a free radical-mediated reduction in pulmonary nitric oxide bioavailability. J Physiol 2010, 588(Pt 23):4837-4847.
123. Penaloza D., Arias-Stella J. The heart and pulmonary circulation at high altitudes: healthy highlanders and chronic mountain sickness. Circulation 2007, 115(9):1132-1146.
124. Becattini C., Agnelli G., Pesavento R., et al. Incidence of chronic thromboembolic pulmonary hypertension after a first episode of pulmonary embolism. Chest 2006, 130(1):172-175.
125. Pengo V., Lensing A.W., Prins M.H., et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004, 350(22):2257-2264.
126. Piazza G., Goldhaber S.Z. Chronic thromboembolic pulmonary hypertension. N Engl J Med 2011, 364(4):351-360.
127. Kline J.A., Steuerwald M.T., Marchick M.R., et al. Prospective evaluation of right ventricular function and functional status 6 months after acute submassive pulmonary embolism: frequency of persistent or subsequent elevation in estimated pulmonary artery pressure. Chest 2009, 136(5):1202-1210.
128. Pepke-Zaba J., Delcroix M., Lang I., et al. Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation 2011, 124(18):1973-1981.
129. Dentali F., Donadini M., Gianni M., et al. Incidence of chronic pulmonary hypertension in patients with previous pulmonary embolism. Thromb Res 2009, 124(3):256-258.
130. Moser K.M., Braunwald N.S. Successful surgical intervention in severe chronic thromboembolic pulmonary hypertension. Chest 1973, 64(1):29-35.
131. Hoeper M.M., Mayer E., Simonneau G., et al. Chronic thromboembolic pulmonary hypertension. Circulation 2006, 113(16):2011-2020.
132. Jamieson S.W., Kapelanski D.P., Sakakibara N., et al. Pulmonary endarterectomy: experience and lessons learned in 1,500 cases. Ann Thorac Surg 2003, 76(5):1457-1462. [discussion: 1462-4].
133. Lewczuk J., Piszko P., Jagas J., et al. Prognostic factors in medically treated patients with chronic pulmonary embolism. Chest 2001, 119(3):818-823.
134. Mayer E., Jenkins D., Lindner J., et al. Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. J Thorac Cardiovasc Surg 2011, 141(3):702-710.
135. Dingli D., Utz J.P., Krowka M.J., et al. Unexplained pulmonary hypertension in chronic myeloproliferative disorders. Chest 2001, 120(3):801-808.
136. Jais X., Ioos V., Jardim C., et al. Splenectomy and chronic thromboembolic pulmonary hypertension. Thorax 2005, 60(12):1031-1034.
137. Bonderman D., Wilkens H., Wakounig S., et al. Risk factors for chronic thromboembolic pulmonary hypertension. Eur Respir J 2009, 33(2):325-331.
138. Guilpain P., Montani D., Damaj G., et al. Pulmonary hypertension associated with myeloproliferative disorders: a retrospective study of ten cases. Respiration 2008, 76(3):295-302.
139. Hoeper M.M., Niedermeyer J., Hoffmeyer F., et al. Pulmonary hypertension after splenectomy?. Ann Intern Med 1999, 130(6):506-509.
140. Bourbonnais J.M., Samavati L. Clinical predictors of pulmonary hypertension in sarcoidosis. Eur Respir J 2008, 32(2):296-302.
141. Gluskowski J., Hawrylkiewicz I., Zych D., et al. Pulmonary haemodynamics at rest and during exercise in patients with sarcoidosis. Respiration 1984, 46(1):26-32.
142. Handa T., Nagai S., Miki S., et al. Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis. Chest 2006, 129(5):1246-1252.
143. Nunes H., Humbert M., Capron F., et al. Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Thorax 2006, 61(1):68-74.
144. Dauriat G., Mal H., Thabut G., et al. Lung transplantation for pulmonary Langerhans' cell histiocytosis: a multicenter analysis. Transplantation 2006, 81(5):746-750.
145. Fartoukh M., Humbert M., Capron F., et al. Severe pulmonary hypertension in histiocytosis X. Am J Respir Crit Care Med 2000, 161(1):216-223.
146. Harari S., Simonneau G., De Juli E., et al. Prognostic value of pulmonary hypertension in patients with chronic interstitial lung disease referred for lung or heart-lung transplantation. J Heart Lung Transplant 1997, 16(4):460-463.
147. Taveira-DaSilva A.M., Hathaway O.M., Sachdev V., et al. Pulmonary artery pressure in lymphangioleiomyomatosis: an echocardiographic study. Chest 2007, 132(5):1573-1578.
148. Aoki Y., Kodama M., Mezaki T., et al. von Recklinghausen disease complicated by pulmonary hypertension. Chest 2001, 119(5):1606-1608.
149. Engel P.J., Baughman R.P., Menon S.G., et al. Pulmonary hypertension in neurofibromatosis. Am J Cardiol 2007, 99(8):1177-1178.
150. Samuels N., Berkman N., Milgalter E., et al. Pulmonary hypertension secondary to neurofibromatosis: intimal fibrosis versus thromboembolism. Thorax 1999, 54(9):858-859.
151. Simeoni S., Puccetti A., Chilosi M., et al. Type 1 neurofibromatosis complicated by pulmonary artery hypertension: a case report. J Med Invest 2007, 54(3-4):354-358.
152. Stewart D.R., Cogan J.D., Kramer M.R., et al. Is pulmonary arterial hypertension in neurofibromatosis type 1 secondary to a plexogenic arteriopathy?. Chest 2007, 132(3):798-808.
153. Launay D., Souza R., Guillevin L., et al. Pulmonary arterial hypertension in ANCA-associated vasculitis. Sarcoidosis Vasc Diffuse Lung Dis 2006, 23(3):223-228.
154. Chu J.W., Kao P.N., Faul J.L., et al. High prevalence of autoimmune thyroid disease in pulmonary arterial hypertension. Chest 2002, 122(5):1668-1673.
155. Ferris A., Jacobs T., Widlitz A., et al. Pulmonary arterial hypertension and thyroid disease. Chest 2001, 119(6):1980-1981.
156. Kokturk N., Demir N., Demircan S., et al. Pulmonary veno-occlusive disease in a patient with a history of Hashimoto's thyroiditis. Indian J Chest Dis Allied Sci 2005, 47(4):289-292.
157. Li J.H., Safford R.E., Aduen J.F., et al. Pulmonary hypertension and thyroid disease. Chest 2007, 132(3):793-797.
158. Merce J., Ferras S., Oltra C., et al. Cardiovascular abnormalities in hyperthyroidism: a prospective Doppler echocardiographic study. Am J Med 2005, 118(2):126-131.
159. Nakhoul F., Yigla M., Gilman R., et al. The pathogenesis of pulmonary hypertension in haemodialysis patients via arterio-venous access. Nephrol Dial Transplant 2005, 20(8):1686-1692.
160. Yigla M., Nakhoul F., Sabag A., et al. Pulmonary hypertension in patients with end-stage renal disease. Chest 2003, 123(5):1577-1582.
161. Dot J.M., Sztrymf B., Yaici A., et al. Rev Mal Respir 2007, 24(3 Pt 1):359-366. [in French].
162. McCabe J.M., Bhave P.D., McGlothlin D., et al. Running from her past: a case of rapidly progressive dyspnea on exertion. Circulation 2011, 124(21):2355-2361.
163. Davis A.M., Pierson R.N., Loyd J.E. Mediastinal fibrosis. Semin Respir Infect 2001, 16(2):119-130.
164. Goodwin R.A., Nickell J.A., Des Prez R.M. Mediastinal fibrosis complicating healed primary histoplasmosis and tuberculosis. Medicine 1972, 51(3):227-246.
165. Loyd J.E., Tillman B.F., Atkinson J.B., et al. Mediastinal fibrosis complicating histoplasmosis. Medicine 1988, 67(5):295-310.